A Roche Project in Cooperation With the Bng (Association of German Resident Gastroenterologists) for Quality Assurance in the Dual- or Triple-therapy of Chronic Hepatitis C With Peg-(40kd)-Interferon Alfa 2a (Pegasys) at Hepatology Centers

Trial Profile

A Roche Project in Cooperation With the Bng (Association of German Resident Gastroenterologists) for Quality Assurance in the Dual- or Triple-therapy of Chronic Hepatitis C With Peg-(40kd)-Interferon Alfa 2a (Pegasys) at Hepatology Centers

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 04 Mar 2016

At a glance

  • Drugs Peginterferon alfa-2a (Primary) ; Ribavirin (Primary) ; Hepatitis C protease inhibitors
  • Indications Chronic hepatitis
  • Focus Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 11 May 2015 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov record.
    • 02 Apr 2015 According to the ClinicalTrials.gov record, status changed from recruiting to active, no longer recruiting.
    • 16 Mar 2015 Status changed from active, no longer recruiting to recruiting, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top